ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41019366

Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy.

Liu Y and 5 others. iScience, 2025. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy. Papers, record 41019366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41019366

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy.
PubMed
Journal
iScience
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-10-01
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu YYongshun
2Huang WWenpeng
3Hsu JCJessica C
4Sun ZZhaonan
5Cai WWeibo
6Kang LLei

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References119

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,275,266High-Responsivity, Fast, and Self-Powered Narrowband Perovskite Heterojunction Photodetectors with a Tunable Response Range in the Visible and Near-Infrared Region.ACS Appl Mater Interfaces2021https://conductscience.org/library/papers/34275266PubMed
220,554,734131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.J Nucl Med2010https://conductscience.org/library/papers/20554734PubMed
333,792,195Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer.ChemMedChem2021https://conductscience.org/library/papers/33792195PubMed
432,301,585Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy.Cancer Commun (Lond)2020https://conductscience.org/library/papers/32301585PubMed
532,807,225The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.J Hematol Oncol2020https://conductscience.org/library/papers/32807225PubMed
635,858,710NIR fluorescence imaging and treatment for cancer immunotherapy.J Immunother Cancer2022https://conductscience.org/library/papers/35858710PubMed
738,252,906Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.Blood2024https://conductscience.org/library/papers/38252906PubMed
829,400,695Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis.J Clin Invest2018https://conductscience.org/library/papers/29400695PubMed
923,900,716Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.Int J Cancer2014https://conductscience.org/library/papers/23900716PubMed
1031,478,503Antibody-drug conjugates for cancer.Lancet2019https://conductscience.org/library/papers/31478503PubMed

1 to 10 of 119

See all 119 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42,980,888Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42980888PubMed
42,782,563Claudin 18 Immunohistochemistry Expression in Salivary Gland Neoplasms: Limited Potential as a Therapeutic Biomarker.Head Neck Pathol2026https://conductscience.org/library/papers/42782563PubMed
42,684,577Research Progress and Optimization Strategies of Bispecific Antibody Therapies for CLDN18.2-Positive Gastric Cancer.J Gastrointest Cancer2026https://conductscience.org/library/papers/42684577PubMed
42,649,986Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers (Basel)2026https://conductscience.org/library/papers/42649986PubMed
42,623,408CLDN18.2 antibody design with protein language models: A deep learning optimization framework.PLoS Comput Biol2026https://conductscience.org/library/papers/42623408PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41019366

GET https://conductscience.org/api/papers/v1/41019366/references?page=2

API referenceFor AI assistants